Peg300

Ponatinib, 33a, 36a, and vehicle (compound formulation) were administered by oral gavage at final volume of 50 μL per mice for each administration. All the animal studies were performed using the same compound formulation with 5% of the volume with DMSO (MPbio, catalog no. 196055) and diluted in 25:70 (%:%) Polyethylene glycol (PEG300, Acros Organics, catalog no. 19222010) (PEG):Olive Oil (Kirkland Signature Pure Olive Oil). The vehicle control was 5% DMSO, 25% PEG and 70% Olive Oil. All compounds were formulated just prior to oral administration by solubilizing the compounds. Individual doses were preheated for 5 minutes at 37°C and vortexed for 15 seconds before administration to ensure a clear homogenous aspect of the solutions. The oral gavage was performed under anesthesia with isoflurane USP (Vet one, Fluriso, NDC 1398504660). The mice were placed in anesthesia induction chambers for approximately 5 minutes until the mice were completely anesthetized using approximately 1.5% isoflurane concentration and 0.5 L per minute oxygen flow rate. The compound administration was performed with 1 mL insulin syringes (Becton Dickinson) with plastic feeding tubes (18 ga × 30 mm; FPT-18–30–50, Instech Laboratories, Inc.).